Search results for " investigation"

showing 10 items of 289 documents

Nonlinear FE analysis of out-of-plane behaviour of masonry walls with and without CFRP reinforcement

2014

Abstract The out-of-plane behaviour of unreinforced and CFRP reinforced masonry wall is studied by means of experimental investigation and numerical FE modelling. The latter is based on a linear constitutive law both for ashlars and mortar joints constituting masonry and the lines of potential delamination are taken into account by means of an interface element with bi-linear law, reproducing the opening failure mode. When reinforcement is introduced, an interface element with bi-linear law is also used, reproducing sliding failure mode. Comparison between numerical and experimental results show the reliability of the modelling. Moreover, a parametric analysis is carried out in order to inv…

Numerical analysis Experimental investigation Masonry wall CFRP reinforcement Interface behaviour Out-of-plane behaviourMaterials sciencebusiness.industryNumerical analysisConstitutive equationDelaminationBuilding and ConstructionStructural engineeringMasonrySettore ICAR/09 - Tecnica Delle CostruzioniNonlinear systemGeneral Materials ScienceMortarComposite materialReinforcementbusinessFailure mode and effects analysisCivil and Structural EngineeringConstruction and Building Materials
researchProduct

Pembrolizumab in First-line Gastric Cancer: Win, Lose, or Draw?

2020

IMPORTANCE: Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need. OBJECTIVE: To evaluate the antitumor activity of pembrolizumab, pembrolizumab plus chemotherapy, or chemotherapy alone in patients with untreated, advanced G/GEJ cancer with programmed cell death ligand 1 (PD-L1) combined positive score (CPS) of 1 or greater. DESIGN, SETTING, AND PARTICIPANTS: The phase 3 KEYNOTE-062 randomized, controlled, partially blinded interventional trial enrolled 763 patients with untreated, locally advanced/unresectable or metastatic G/GEJ cancer with PD-L1 CPS of 1 or greater from 200 centers in 29 countries between September 18, …

OncologyCancer Researchmedicine.medical_specialtyCell cycle checkpointbusiness.industryFirst lineMEDLINECancerPembrolizumabAdenocarcinomamedicine.diseaseAntibodies Monoclonal HumanizedText miningOncologyStomach NeoplasmsInternal medicineMonoclonalMedicineAdenocarcinomaHumansbusinessOriginal InvestigationJAMA oncology
researchProduct

Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Canc…

2019

Question What are the outcomes of haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy compared with other transplant types in adults with hematologic cancers? Findings In this meta-analysis of 30 studies including 22974 patients, the use of haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy appeared to show increased all-cause mortality compared with matched related donors, similar all-cause mortality compared with matched unrelated donors, and reduced all-cause mortality compared with mismatched unrelated donors. Relapse appeared to be increased in lymphoma and similar in acute leukemia compared with matched unrelated don…

OncologyCancer Researchmedicine.medical_specialtyCyclophosphamidebusiness.industrymedicine.medical_treatmentOdds ratioHematopoietic stem cell transplantationCochrane LibraryTransplantation03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineMeta-analysismedicine030212 general & internal medicineStem cellbusinessCyclophosphamide therapymedicine.drugOriginal Investigation
researchProduct

Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT…

2021

Abstract Background Embryonal tumors with multilayered rosettes (ETMR) are highly aggressive tumors occurring in early childhood. Published clinical data refer to retrospective, heterogeneously treated cohorts. Here, we describe the outcome of patients treated according to the prospective P-HIT trial and subsequent HIT2000-interim-registry. Patients and methods Age-stratified treatment included carboplatin/etoposide induction, tandem high-dose chemotherapy (“CARBO/ETO + HDCT”), and response-stratified radiotherapy. Patients with centrally reviewed neuropathological and molecularly confirmed diagnosis of ETMR recruited within the P-HIT trial (2001-2011; n = 19), the HIT2000-interim-registry …

OncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentMedizinClinical InvestigationsImproved survival610 Medicine & healthBrain Neoplasms/drug therapyCentral Nervous System NeoplasmsHigh dose chemotherapychemistry.chemical_compoundCarboplatin/therapeutic useInternal medicinemedicineHigh-dose chemotherapyHumansNeuroectodermal Tumors Primitive1306 Cancer ResearchProspective StudiesChildOutcomeEtoposideRetrospective StudiesChemotherapyddc:618business.industryBrain NeoplasmsIncidence (epidemiology)IncidenceInfantInduction ChemotherapyNeoplasms Germ Cell and EmbryonalCarboplatinETMRRadiation therapyClinical trialClinical trial2728 Neurology (clinical)Oncologychemistry10036 Medical ClinicChild Preschool2730 OncologyNeurology (clinical)Antineoplastic Combined Chemotherapy Protocols/therapeutic usebusinessCarboplatin/etoposideNeoplasms Germ Cell and Embryonal/drug therapy
researchProduct

Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts

2018

Source at https://doi.org/10.1186/s13058-018-1073-0. Licensed CC BY-NC-ND 4.0. Background: Few published breast cancer (BC) risk prediction models consider the heterogeneity of predictor variables between estrogen-receptor positive (ER+) and negative (ER-) tumors. Using data from two large cohorts, we examined whether modeling this heterogeneity could improve prediction. Methods: We built two models, for ER+ (ModelER+) and ER- tumors (ModelER-) , respectively, in 281,330 women (51% postmenopausal at recruitment) from the European Prospective Investigation into Cancer and Nutrition cohort. Discrimination (C-statistic) and calibration (the agreement between predicted and observed tumor risks)…

OncologyHORMONE-REPLACEMENT THERAPYmedicine.medical_treatmentWHI0302 clinical medicineBreast cancerRisk FactorsEstrogen receptor030212 general & internal medicineProspective StudiesProspective cohort study2. Zero hungerIncidenceHormone replacement therapy (menopause)Middle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisRisk prediction3. Good healthEuropean Prospective Investigation into Cancer and NutritionMenopausePOSTMENOPAUSAL WOMENReceptors EstrogenPLUS PROGESTIN030220 oncology & carcinogenesisCohortFemaleRisk assessmentResearch Articlemedicine.medical_specialtyMODELSAntineoplastic AgentsBreast NeoplasmsEstrògenslcsh:RC254-282Models BiologicalRisk AssessmentVALIDATIONCàncer de mamaMAMMOGRAPHY03 medical and health sciencesBreast cancerInternal medicinemedicineHumansOncology & CarcinogenesisCancer och onkologiVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762business.industryMORTALITYKirurgiProspective cohortmedicine.diseaseEstrogenVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762Cancer and OncologySurgerybusinessEPIC1112 Oncology And CarcinogenesisBody mass indexFollow-Up StudiesBreast Cancer Research : BCR
researchProduct

Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIO…

2013

BackgroundThis multicenter phase II study investigated temozolomide + irinotecan (TEMIRI) treatment in children with relapsed or refractory medulloblastoma.MethodsPatients received temozolomide 100–125 mg/m2/day (days 1–5) and irinotecan 10 mg/m2/day (days 1–5 and 8–12) every 3 weeks. The primary endpoint was tumor response within the first 4 cycles confirmed ≥4 weeks and assessed by an external response review committee (ERRC). In a 2-stage Optimum Simon design, ≥6 responses in the first 15 evaluable patients were required within the first 4 cycles for continued enrollment; a total of 19 responses from the first 46 evaluable patients was considered successful.ResultsSixty-six patients were…

OncologyMaleCancer Researchmedicine.medical_specialtyAdolescentmedicine.medical_treatmentClinical InvestigationsPhases of clinical researchtemozolomideNeutropeniaIrinotecanmedulloblastomaTEMIRIInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansCerebellar NeoplasmsChildChemotherapyTemozolomidebusiness.industrymedicine.diseaseChemotherapy regimenSurgeryIrinotecanDacarbazineOncologyTolerabilityChild PreschoolCamptothecinFemaleNeurology (clinical)businessmedicine.drug
researchProduct

Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials

2005

In the last two decades the results of medical treatment of advanced non-small cell lung cancer (NSCLC) have constantly improved even if they are still far from being considered satisfactory. Today systemic cisplatin-based chemotherapy (CT) is able to increase survival and improve cancer-related symptoms in patients with advanced ‘wet’ stage III and metastatic stage IV NSCLC, but it not clear if the benefits of CT also apply to patients with poor performance status (PS) [1, 2]. PS is the most powerful independent prognostic factor in advanced NSCLC since it is a reliable measure of functional independence, ability to perform daily activities and work, and a strong predictor of survival and …

Oncologymedicine.medical_specialtyLung Neoplasmsbusiness.industryDrugs Investigationallung cancer performance status 2 chemotherapy best supportive careHematologymedicine.diseaseClinical trialRegimenOncologyQuality of lifeCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansControlled Clinical Trials as TopicStage (cooking)Lung cancerbusinessAdverse effectSurvival rateSurvival analysisNeoplasm StagingAnnals of Oncology
researchProduct

OPTIMA Newsletter 39(1-2)

2010

Organization Phytotaxonomic Investigation Mediterranean Area
researchProduct

OPTIMA Newsletter 40(1-2)

2011

Organization Phytotaxonomic Investigation Mediterranean Area
researchProduct

An Alternative to the Human Hemoglobin Test in the Investigation of Bloodstains Treated with Active Oxygen: The Human Glycophorin A Test

2011

In criminal investigations, there are three stages involved when studying bloodstains: search and orientation, confirmation, and individualization. Confirmatory tests have two aims: to show that the stain contains a human biological fluid and to confirm the type of biological fluid. The need to determine the nature of the evidence is reflected in the latest bibliography, where the possibility of employing mRNA and miRNA markers for this purpose is proposed. While these new proposals are being investigated, the kits for determining human hemoglobin currently provide a simple solution for resolving this issue. With these kits, the possibility of obtaining false positives and false negatives i…

Pathologymedicine.medical_specialtyArticle Subjectforensic sciencesCarbonateslcsh:MedicineStainlcsh:TechnologyGeneral Biochemistry Genetics and Molecular BiologyBiological fluidhuman glycophorin A testmedicineGlycophorinHumansGlycophorinslcsh:ScienceGeneral Environmental Sciencehuman hemoglobin testbiologyHuman bloodlcsh:Tlcsh:RGeneral MedicineForensic MedicineActive oxygenBiochemistryBlood Stainsbloodstains investigationbiology.proteinlcsh:QHemoglobinResearch ArticleThe Scientific World Journal
researchProduct